KaydedilenlerDerginizi ekleyin

Dergiler / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Fibromyalgia syndrome and related factors in hemodialysis, peritoneal dialysis, and renal transplant patients: A cross-sectional study

Ayla ÇAĞLIYAN TÜRK
Sultan ÖZKURT
İbrahim DOĞAN
Sayfa
67–76
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There was a significant difference in the point prevalence of fibromyalgia between the hemodialysis group and healthy controls (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:transplantation compared to healthy controls and to evaluate depressive symptoms, anxiety level, and the impact of fibromyalgia on quality of life (QoL).
📊
Temel Bulgular & Veri:Patients and methods: Between January 2018 and January 2019, a total of 107 hemodialysis patients (Group 1) (48 males, 59 females; median age: 50 years; range, 42 to 56 years), 51 peritoneal dialysis patients (Group 2) (32 males, 19 females; median age: 49 years; range, 39 to 54 years), 52 renal transplant patients (Group 3) (23 males, 29 females; median age: 45.5 years; range, 37 to 52 years), and 50 healthy controls (Group 4) (23 males, 27 females; median age: 46.5 years; range, 42 to 50 years) were included in the study.
💡
Sonuç & Katkı:There was a significant difference in the point prevalence of fibromyalgia between the hemodialysis group and healthy controls (p
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

transplantation compared to healthy controls and to evaluate depressive symptoms, anxiety level, and the impact of fibromyalgia on quality of life (QoL). Patients and methods: Between January 2018 and January 2019, a total of 107 hemodialysis patients (Group 1) (48 males, 59 females; median age: 50 years; range, 42 to 56 years), 51 peritoneal dialysis patients (Group 2) (32 males, 19 females; median age: 49 years; range, 39 to 54 years), 52 renal transplant patients (Group 3) (23 males, 29 females; median age: 45.5 years; range, 37 to 52 years), and 50 healthy controls (Group 4) (23 males, 27 females; median age: 46.5 years; range, 42 to 50 years) were included in the study. Age, sex, amount of time spent on dialysis, and laboratory data were recorded. Impact of fibromyalgia on QoL was evaluated using the Fibromyalgia Impact Questionnaire (FIQ), while depressive symptoms and anxiety level were assessed using the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI), respectively. Results: The point prevalence of fibromyalgia was 14% in Group 1 (n=15), 5.9% in Group 2 (n=3), 9.6% in Group 3 (n=5), and 4% in Group 4. There was a significant difference in the point prevalence of fibromyalgia between the hemodialysis group and healthy controls (p

🔖

Bu Makaleye Atıf Yap

TÜRK, A. Ç., ÖZKURT, S., DOĞAN, İ. (2022). Fibromyalgia syndrome and related factors in hemodialysis, peritoneal dialysis, and renal transplant patients: A cross-sectional study. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 67–76. https://ajindex.com/articles/447961

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Laurence AB, Alarcon GS. Miscellaneous rheumatic diseases. In: Kopman WJ, Moreland LW, editors. Arthritis and allied conditions. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1869-910
  2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72
  3. Clauw DJ. Fibromyalgia: Update on mechanisms and management. J Clin Rheumatol 2007;13:102-9
  4. Yuceturk TE, Yucel AE, Yuceturk H, Kart-Koseoglu H, Unuvar R, Ozdemir FN, et al. Fibromyalgia: Its prevalence in haemodialysis patients and its relationships with clinical and laboratory parameters. Nephrol Dial Transplant 2005;20:2485-8
  5. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician 2007;76:247-54
  6. Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol 2003;15:48-54
  7. Couto CI, Natour J, Carvalho AB. Fibromyalgia: Its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int 2008;12:66-72
  8. Samimagham H, Haghighi A, Tayebi M, Jenabi A, Arabi M, Kianmehr N. Prevalence of fibromyalgia in hemodialysis patients. Iran J Kidney Dis 2014;8:236-9
  9. Leblebici B, Özelsancak R, Yılmaz EE, Doruk P. Fibromyalgia syndrome in Turkish hemodialysis patients. Hemodial Int 2016;20:106-10
  10. Berber I, Sahin I, Gorgel A, Cagin YF, Bag HG, Berber NK. Effects of renal replacement therapy on fibromyalgia syndrome in patients with chronic kidney disease. Acta Medica Mediterranea 2018;34:337-43
  11. Sargın G, entürk T, Akdam H. Fibromyalgia syndrome in patients undergoing peritoneal dialysis and hemodialysis. Sakarya Tıp Dergisi 2018;8:657-62
  12. Erkmen Uyar M, Sezer S, Bal Z, Guliyev O, Tutal E, Genctoy G, et al. Fibromyalgia and its clinical relevance in renal transplant recipients. Transplant Proc 2015;47:1105-9
  13. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
  14. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18:728-33
  15. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12